| 发布于: | 雪球 | 回复：8 | 喜欢：0 |
理查德·埃布赖特，是美国罗格斯大学的生物学家，他说没有任何一个国家，没有任何公司能够与药明康德的能力与业绩相匹配。$药明生物(02269)$
He served for sixteen years as editor of the Journal of Molecular Biology. He has served on the National Institutes of Health Molecular Biology Study Section and on National Institutes of Health special emphasis panels. He is a member of the Institutional Biosafety Committee of Rutgers University, and he has been a member of the Antimicrobial Resistance Committee of the Infectious Diseases Society of America, the Working Group on Pathogen Security of the state of New Jersey, and the Controlling Dangerous Pathogens Project of the Center for International Security Studies. He has testified at US House and US Senate hearings on biosafety, biosecurity, and biorisk management.
这些项目是近几年积累的，说明订单的增长大于客户的交付量，公司未来的业绩有保障。至于你说合作商方面，哪么就要看项目处于哪个阶段，如果有些客户需要提供全流程端到端服务，哪么从CRO的最前端到项目的商业化过程十年左右的时间也正常。$药明生物(02269)$